Although another group could identify MAGL expression in healthy melanocytes as well [155], these findings invite new studies exploring if MAGL-inhibitors (and e.g., the subsequently enhanced/restored CB2 signaling) may be effective in the management of cutaneous melanoma. Here, MGLL is linked to cutaneous melanoma.